ME00565A - Topically applicable pharmaceutical preparation - Google Patents

Topically applicable pharmaceutical preparation

Info

Publication number: ME00565A
Authority: ME; Montenegro
Prior art keywords: pharmaceutical preparation; topically applicable; applicable pharmaceutical; topically; administering
Prior art date: 2002-05-28

Application number

MEP-854/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Christina Bolle

Rudolf Linder

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-28

Filing date

2003-05-27

Publication date

2011-12-20

2003-05-27 Application filed filed Critical

2011-12-20 Publication of ME00565A publication Critical patent/ME00565A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dispersion Chemistry (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MEP-854/08A 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation ME00565A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE10223828		2002-05-28
EP02011830		2002-05-28
DE10311613		2003-03-14
YUP-1014/04A RS51104B (sr)	2002-05-28	2003-05-27	Farmaceutski preparat za topičnu primenu
PCT/EP2003/005524 WO2003099334A1 (en)	2002-05-28	2003-05-27	Topically applicable pharmaceutical preparation

Publications (1)

Publication Number	Publication Date
ME00565A true ME00565A (en)	2011-12-20

Family

ID=29587313

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-854/08A ME00565A (en)	2002-05-28	2003-05-27	Topically applicable pharmaceutical preparation

Country Status (32)

Country	Link
US (7)	US20060084685A1 (no)
EP (3)	EP2020243B1 (no)
JP (3)	JP5652983B2 (no)
KR (2)	KR20050014844A (no)
CN (3)	CN101491520B (no)
AT (2)	ATE485821T1 (no)
AU (2)	AU2003232828B2 (no)
BR (2)	BR0311339A (no)
CA (2)	CA2486910C (no)
CY (2)	CY1110312T1 (no)
DE (2)	DE60334692D1 (no)
DK (3)	DK1511516T3 (no)
EA (2)	EA010416B1 (no)
ES (3)	ES2693094T3 (no)
HR (1)	HRP20041211B1 (no)
HU (1)	HUE039709T2 (no)
IL (3)	IL164935A (no)
IS (1)	IS2639B (no)
LT (1)	LT2020243T (no)
MA (1)	MA27813A1 (no)
ME (1)	ME00565A (no)
MX (2)	MXPA04011612A (no)
NO (2)	NO334882B1 (no)
NZ (3)	NZ536920A (no)
PL (3)	PL211870B1 (no)
PT (3)	PT1511481E (no)
RS (1)	RS51104B (no)
SI (2)	SI2020243T1 (no)
TR (1)	TR201815573T4 (no)
UA (2)	UA88523C2 (no)
WO (2)	WO2003099334A1 (no)
ZA (2)	ZA200408649B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872382B1 (en)	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
SI2020243T1 (sl) *	2002-05-28	2018-11-30	Astrazeneca Ab	Farmacevtski pripravek za topično uporabo
BR0314603A (pt)	2002-09-20	2005-07-26	Alcon Inc	Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
FR2851247B1 (fr) *	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
BRPI0406427B8 (pt)	2003-03-10	2021-05-25	Astrazeneca Ab	processo para a preparação de roflumilast
US20070082017A1 (en) *	2004-01-10	2007-04-12	Tseng Scheffer C	Lipid compositions and methods of use
DE102004046236A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
DE102004046235A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
WO2006094933A1 (en) *	2005-03-08	2006-09-14	Nycomed Gmbh	Roflumilast for the treatment of diabetes mellitus
WO2006097456A1 (en) *	2005-03-16	2006-09-21	Nycomed Gmbh	Taste masked dosage form containing roflumilast
WO2006132342A1 (ja) *	2005-06-09	2006-12-14	Santen Pharmaceutical Co., Ltd.	ロフルミラスト点眼液
AU2007218725B2 (en)	2006-02-21	2011-12-01	Eisai R & D Management Co., Ltd.	4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
EP2123641A4 (en)	2007-02-16	2011-06-22	Eisai R&D Man Co Ltd	CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT
US8513269B2 (en)	2007-08-17	2013-08-20	Eisai R&D Management Co., Ltd.	Preparation for external use
KR20100042245A (ko)	2007-08-17	2010-04-23	에자이 알앤드디 매니지먼트 가부시키가이샤	퀴나졸린 유도체의 제조 방법
AU2010318687B2 (en)	2009-10-30	2016-02-25	Nestec S.A.	Methods for maintaining eye health and ameliorating opthalmic maladies in canines
ES2408132B1 (es) *	2010-09-08	2014-04-04	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento de la epífora.
ES2377785B2 (es)	2010-09-08	2012-09-26	Universidad Miguel Hernández De Elche	Composición farmacéutica para el tratamiento del ojo seco.
ES2711100T3 (es)	2011-03-07	2019-04-30	Celgene Corp	Métodos para tratar enfermedades usando compuestos isoindolina
CN102793684B (zh) *	2011-05-26	2016-02-17	杭州赛利药物研究所有限公司	罗氟司特液体制剂及其制备方法
CU24163B1 (es) *	2011-06-28	2016-03-31	Bayer Healthcare Llc	Composición farmacéutica oftalmológica tópica que contiene regorafenib
CN104379180A (zh) *	2012-04-10	2015-02-25	佐治亚州立大学研究基金会公司	用cyld抑制剂治疗中耳炎及其它病状的组合物和方法
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
CN103570610B (zh) *	2012-07-18	2017-08-11	重庆华邦制药有限公司	一种罗氟司特微粒的制备方法
EA035391B1 (ru)	2012-11-08	2020-06-05	Ризен Фармасьютикалз Са	Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
TW201540301A (zh)	2013-08-16	2015-11-01	Takeda Gmbh	以ｐｄｅ４抑制劑治療認知損傷
CN105434328A (zh) *	2014-09-01	2016-03-30	天津药物研究院有限公司	一种含罗氟司特固体分散体的固体制剂及其制备方法
ES2777550T3 (es)	2014-10-24	2020-08-05	Hisamitsu Pharmaceutical Co	Profármaco de roflumilast
CN104997959A (zh) *	2015-08-21	2015-10-28	蔡宇平	一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) *	2016-07-11	2019-10-01	赵晨	一种遗传性Usher综合征的致病突变及其检测试剂
US20210161870A1 (en)	2017-06-07	2021-06-03	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en)	2017-06-07	2018-02-20	Arcutis, Inc.	Inhibition of crystal growth of roflumilast
US11129818B2 (en)	2017-06-07	2021-09-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) *	2018-11-16	2020-05-21	Arcutis, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en)	2017-06-07	2024-06-18	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en)	2018-11-16	2024-07-23	Arcutis Biotherapeutics, Inc.	Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en)	2017-09-22	2022-12-27	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) *	2018-03-13	2018-07-17	兆科药业（广州）有限公司	一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
JP7492918B2 (ja)	2018-06-04	2024-05-30	アーキュティス・バイオセラピューティクス・インコーポレーテッド	ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
KR102117525B1 (ko) *	2018-07-09	2020-06-01	건양대학교 산학협력단	Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
MX2022009399A (es)	2020-01-31	2022-09-19	Arcutis Biotherapeutics Inc	Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica.
WO2021226370A1 (en) *	2020-05-07	2021-11-11	Arcutis Biotherapeutics, Inc.	Treatment of skin conditions using high krafft temperature anionic surfactants
CN116963717A (zh)	2020-12-04	2023-10-27	阿尔库缇斯生物疗法股份有限公司	具有抗真菌性能的局部用罗氟司特制剂
WO2022169615A1 (en)	2021-02-05	2022-08-11	Arcutis Biotherapeutics, Inc.	Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (zh) *	2021-02-10	2023-10-10	洛利克斯治疗有限公司	眼部递送罗氟司特的方法
AU2022218993A1 (en)	2021-02-10	2023-08-03	Iolyx Therapeutics, Inc.	Methods for ophthalmic delivery of roflumilast
JP2024520701A (ja) *	2021-06-01	2024-05-24	アイディアバイオ，エルエルシー	眼科薬の長期放出薬物送達システムおよび使用方法
EP4405048A4 (en) *	2021-09-22	2025-08-06	Iolyx Therapeutics Inc	METHODS OF TREATMENT OF INFLAMMATORY EYE DISEASES
KR20240121320A (ko)	2021-12-17	2024-08-08	에어리 파마슈티컬즈, 인코포레이티드	안과용 약학 조성물 및 이의 용도
WO2023129215A1 (en)	2021-12-28	2023-07-06	Arcutis Biotherapeutics, Inc.	Topical roflumilast aerosol foams
EP4586999A1 (en)	2022-09-15	2025-07-23	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
US20250082618A1 (en)	2023-09-07	2025-03-13	Arcutis Biotherapeutics, Inc.	Dosing regimens using topical roflumilast compositions
WO2025059531A1 (en)	2023-09-15	2025-03-20	Arcutis Biotherapeutics, Inc.	Topical roflumilast for the treatment of atopic/seborrheic dermatitis
WO2025080415A1 (en)	2023-10-12	2025-04-17	Alto Neuroscience, Inc.	Treatment of neuropsychiatric disorders with tilivapram
CN117462487A (zh) *	2023-11-29	2024-01-30	沈阳药科大学	一种罗氟司特油凝胶及其制备方法
WO2025221488A1 (en)	2024-04-16	2025-10-23	Alto Neuroscience, Inc.	Transdermal administration of pde4 inhibitors for reduction in adverse events
WO2025265054A2 (en)	2024-06-21	2025-12-26	Arcutis Biotherapeutics, Inc.	Methods of treatment using topical roflumilast compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753945A (en) *	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) *	1988-05-31	1991-04-30	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) *	1992-09-14	1999-04-06	Wolf-Georg Forssmann	Use of inhibitors of phosphodiesterase IV
SI0706513T1 (en) *	1993-07-02	2002-10-31	Altana Pharma Ag	Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
EP0719561A4 (en) *	1993-08-10	1997-07-30	Fujisawa Pharmaceutical Co	Percutaneous absorbent preparation
ZA954599B (en) *	1994-06-07	1996-01-26	Allergan Inc	Stable gel formulation for topical treatment of skin conditions
EP1118615A4 (en) *	1998-09-29	2002-02-27	Fujisawa Pharmaceutical Co	PYRIDOPYRAZINE DERIVATIVES SALTS AND CRYSTALS THEREOF
US6395746B1 (en) *	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) *	1998-10-13	2002-01-17	John Kung	Composition to enhance permeation of topical skin agents
DK1161239T3 (da)	1999-03-10	2005-02-14	Altana Pharma Ag	3- cyclopropylmethoxy-4-difluormethoxy-N-(3,5-dichlorpyrid-4-yl)benzamid til behandling af dissemineret sklerose
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain
CZ20021443A3 (cs) *	1999-10-29	2003-01-15	Smithkline Beecham Corporation	Způsob podávání inhibitoru fosfodiesterázy 4
PL357555A1 (en) *	2000-01-31	2004-07-26	Pfizer Products Inc.	Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
EP1261331A4 (en) *	2000-02-16	2005-01-05	Univ Nebraska Medical Ct	METHOD AND COMPOSITIONS FOR TREATING FIBROSANT DISEASES
JP2003534328A (ja) *	2000-05-25	2003-11-18	メルクフロストカナダアンドカンパニー	フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
CA2427814C (en) *	2000-11-07	2009-06-02	Merck & Co., Inc.	A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) *	2001-05-21	2005-03-29	Alcon, Inc.	Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) *	2001-11-09	2003-05-15	Johannes Barsig	Combination
SI2020243T1 (sl) *	2002-05-28	2018-11-30	Astrazeneca Ab	Farmacevtski pripravek za topično uporabo

2003
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Ceased
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/en not_active Expired - Lifetime
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en not_active Ceased
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active Expired - Fee Related
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 EP EP03755048A patent/EP1511516B1/en not_active Expired - Lifetime
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 EP EP03730122A patent/EP1511481B1/en not_active Expired - Lifetime
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en not_active Ceased
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL165065A (en)	2010-11-30
ATE417628T1 (de)	2009-01-15
EA020569B1 (ru)	2014-12-30
US20080280958A1 (en)	2008-11-13
RS51104B (sr)	2010-10-31
KR20110122230A (ko)	2011-11-09
RS101404A (sr)	2007-02-05
SI1511516T1 (sl)	2009-06-30
US20110313005A1 (en)	2011-12-22
EP1511516B1 (en)	2008-12-17
CY1110312T1 (el)	2015-01-14
WO2003099334A1 (en)	2003-12-04
MXPA04011528A (es)	2005-02-14
PL212134B1 (pl)	2012-08-31
NO334882B1 (no)	2014-06-30
US20060084685A1 (en)	2006-04-20
AU2003232828A1 (en)	2003-12-12
PT1511481E (pt)	2011-01-14
JP2012229245A (ja)	2012-11-22
EP1511516A1 (en)	2005-03-09
NZ536920A (en)	2007-04-27
EP1511481B1 (en)	2010-10-27
CA2486917C (en)	2011-11-22
ATE485821T1 (de)	2010-11-15
IL209657A0 (en)	2011-02-28
HRP20041211B1 (hr)	2013-06-30
ZA200408649B (en)	2007-12-27
JP5652983B2 (ja)	2015-01-14
HUE039709T2 (hu)	2019-01-28
ES2319517T3 (es)	2009-05-08
IL164935A (en)	2010-12-30
EP1511481A1 (en)	2005-03-09
US20210116207A1 (en)	2021-04-22
CA2486917A1 (en)	2003-12-04
EP2020243A1 (en)	2009-02-04
TR201815573T4 (tr)	2018-11-21
DK2020243T3 (en)	2018-11-19
US20060084684A1 (en)	2006-04-20
WO2003099278A1 (en)	2003-12-04
CN101491520A (zh)	2009-07-29
BR0311337A (pt)	2005-03-15
NZ553731A (en)	2007-07-27
AU2003232828B2 (en)	2010-06-24
CN100490804C (zh)	2009-05-27
US20190029956A1 (en)	2019-01-31
AU2003240719A1 (en)	2003-12-12
EA010416B1 (ru)	2008-08-29
EA200401517A1 (ru)	2005-06-30
IS7612A (is)	2004-12-23
JP5683538B2 (ja)	2015-03-11
KR101307093B1 (ko)	2013-09-11
MA27813A1 (fr)	2006-04-03
HRP20041211A2 (hr)	2006-04-30
NZ537308A (en)	2009-09-25
HK1079437A1 (en)	2006-04-07
PL372095A1 (en)	2005-07-11
DE60325354D1 (de)	2009-01-29
ES2354971T3 (es)	2011-03-21
UA88523C2 (ru)	2009-10-26
PL211870B1 (pl)	2012-07-31
NO20045656L (no)	2004-12-27
KR20050014844A (ko)	2005-02-07
EP2020243B1 (en)	2018-08-15
LT2020243T (lt)	2018-11-12
CN1655823B (zh)	2010-05-26
BR0311339A (pt)	2005-03-22
IL165065A0 (en)	2005-12-18
IS2639B (is)	2010-06-15
US20140303215A1 (en)	2014-10-09
CN1655782A (zh)	2005-08-17
DE60334692D1 (de)	2010-12-09
JP2005529930A (ja)	2005-10-06
ES2693094T3 (es)	2018-12-07
MXPA04011612A (es)	2005-03-07
IL164935A0 (en)	2005-12-18
CA2486910C (en)	2011-11-29
PL372082A1 (en)	2005-07-11
HK1079445A1 (zh)	2006-04-07
UA81910C2 (uk)	2008-02-25
NO20045506L (no)	2004-12-16
EA200702588A1 (ru)	2008-08-29
AU2003240719B2 (en)	2009-12-10
CA2486910A1 (en)	2003-12-04
DK1511516T3 (da)	2009-04-06
NO334916B1 (no)	2014-07-14
SI2020243T1 (sl)	2018-11-30
PT1511516E (pt)	2009-02-20
CN101491520B (zh)	2011-03-16
PT2020243T (pt)	2018-11-09
ZA200409584B (en)	2006-05-31
CY1121133T1 (el)	2019-12-11
PL397021A1 (pl)	2012-03-26
DK1511481T3 (da)	2011-01-24
CN1655823A (zh)	2005-08-17
JP2005529928A (ja)	2005-10-06

Publication	Publication Date	Title
ZA200409584B (en)	2006-05-31	Topically applicable pharmaceutical preparation
AU1708202A (en)	2002-06-18	Organic compounds
UA84266C2 (uk)	2008-10-10	Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
AU2002211863A1 (en)	2002-04-15	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
YU58103A (sh)	2006-03-03	Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
CA2301017A1 (en)	1999-03-11	Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
PL377478A1 (pl)	2006-02-06	Cykloalkenowe kwasy dikarboksylowe jako środki przeciwzapalne, immunomodulujące oraz antyproliferacyjne
MY135646A (en)	2008-06-30	Indolyl derivatives
TNSN06220A1 (en)	2007-12-03	Benzimidazole derivatives
WO2002004012A8 (en)	2002-04-04	Anhydrous pharmaceutical composition of vancomycin for topical use
WO2002040477A3 (en)	2003-02-27	Saframycins, analogues and uses thereof
ECSP045447A (es)	2005-01-28	Preparación farmacéutica que se puede aplicar por vía tópica